Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity

Molecular Therapy

Volumn 17, Issue 9, 2009, Pages 1626-1636

  Lapteva, Natalia ^a,b   Aldrich, Melissa ^a,b   Rollins, Lisa ^a,b   Ren, Wenhong ^a,b   Goltsova, Tatiana ^a   Chen, Si Yi ^a,b   Huang, Xue F ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER IMMUNIZATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL THERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; BETA-DEFENSINS; BLOTTING, WESTERN; CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS; ONCOLYTIC VIRUSES;

ADENOVIRIDAE; MUS;

EID: 69949180750     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.111     Document Type: Article

References (50)

1. Stoler, DL, Chen, N, Basik, M, Kahlenberg, MS, Rodriguez-Bigas, MA, Petrelli, NJ et al. (1999). The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 96: 15121-15126.
2. Hanada, K, Yewdell, JW and Yang, JC (2004). Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427: 252-256.
3. Vigneron, N, Stroobant, V, Chapiro, J, Ooms, A, Degiovanni, G, Morel, S et al. (2004). An antigenic peptide produced by peptide splicing in the proteasome. Science 304: 587-590.
4. Pardoll, DM (1999). Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96: 5340-5342.
5. Bowne, WB, Srinivasan, R, Wolchok, JD, Hawkins, WG, Blachere, NE, Dyall, R et al. (1999). Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190: 1717-1722.
6. Banchereau, J and Steinman, RM (1998). Dendritic cells and the control of immunity. Nature 392: 245-252.
7. Steinman, RM (2003). The control of immunity and tolerance by dendritic cell. Pathol Biol 51: 59-60.
8. Behrens, G, Li, M, Smith, CM, Belz, GT, Mintern, J, Carbone, FR et al. (2004). Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 82: 84-90.
9. De Smedt, T, Pajak, B, Muraille, E, Lespagnard, L, Heinen, E, De Baetselier, P et al. (1996). Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184: 1413-1424.
10. Akbari, O, Panjwani, N, Garcia, S, Tascon, R, Lowrie, D and Stockinger, B (1999). DNA vaccination: Transfection and activation of dendritic cells as key events for immunity. J Exp Med 189: 169-178.
11. Steinman, RM, Hawiger, D and Nussenzweig, MC (2003). Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
12. Robbiani, DF, Finch, RA, Jäger, D, Muller, WA, Sartorelli, AC and Randolph, GJ (2000). The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103: 757-768.
13. Sozzani, S, Allavena, P, Vecchi, A and Mantovani, A (1999). The role of chemokines in the regulation of dendritic cell trafficking. J Leukoc Biol 66: 1-9.
14. Sozzani, S, Allavena, P, D'Amico, G, Luini, W, Bianchi, G, Kataura, M et al. (1998). Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties. J Immunol 161: 1083-1086.
15. Vermi, W, Bonecchi, R, Facchetti, F, Bianchi, D, Sozzani, S, Festa, S et al. (2003). Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200: 255-268.
16. Bell, D, Chomarat, P, Broyles, D, Netto, G, Harb, GM, Lebecque, S et al. (1999). In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190: 1417-1426.
17. Furumoto, K, Soares, L, Engleman, EG and Merad, M (2004). Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113: 774-783.
18. Biragyn, A, Belyakov, IM, Chow, YH, Dimitrov, DS, Berzofsky, JA and Kwak, LW (2002). DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100: 1153-1159.
19. Biragyn, A, Ruffini, PA, Leifer, CA, Klyushnenkova, E, Shakhov, A, Chertov, O et al. (2002). Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298: 1025-1029.
20. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
21. Heise, C, Hermiston, T, Johnson, L, Brooks, G, Sampson-Johannes, A, Williams, A et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-1139.
22. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
23. Huang, XF, Ren, W, Rollins, L, Pittman, P, Shah, M, Shen, L et al. (2003). A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res 63: 7321-7329.
24. Wang, Y, Hallden, G, Hill, R, Anand, A, Liu, TC, Francis, J et al. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335.
25. Bals, R, Wang, X, Meegalla, RL, Wattler, S, Weiner, DJ, Nehls, MC et al. (1999). Mouse β-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. Infect Immun 67 3542-3547.
26. Biragyn, A, Surenhu, M, Yang, D, Ruffini, PA, Haines, BA, Klyushnenkova, E et al. (2001). Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 167: 6644-6653.
27. Yang, D, Chertov, O, Bykovskaia, SN, Chen, Q, Buffo, MJ, Shogan, J et al. (1999). β-Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286: 525-528.
28. Huang, GT, Zhang, HB, Kim, D, Liu, L and Ganz, T (2002). A model for antimicrobial gene therapy: Demonstration of human β-defensin 2 antimicrobial activities in vivo. Hum Gene Ther 13: 2017-2025.
29. Funderburg, N, Lederman, MM, Feng, Z, Drage, MG, Jadlowsky, J, Harding, CV et al. (2007). Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 104: 18631-18635.
30. Soruri, A, Grigat, J, Forssmann, U, Riggert, J and Zwirner, J (2007). β-Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol 37: 2474-2486.
31. Kadowaki, N, Ho, S, Antonenko, S, Malefyt, RW, Kastelein, RA, Bazan, F et al. (2001). Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194: 863-869.
32. Boonstra, A, Asselin-Paturel, C, Gilliet, M, Crain, C, Trinchieri, G, Liu, YJ et al. (2003). Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: Dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 197: 101-109.
33. Hochrein, H, O'Keeffe, M and Wagner, H (2002). Human and mouse plasmacytoid dendritic cells. Hum Immunol 63: 1103-1110.
34. Brasel, K, De Smedt, T, Smith, JL and Maliszewski, CR (2000). Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96: 3029-3039.
35. + DC1 precursors. Blood 101: 1453-1459.
36. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 194: 1171-1178.
37. Asselin-Paturel, C, Boonstra, A, Dalod, M, Durand, I, Yessaad, N, Dezutter-Dambuyant, C et al. (2001). Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2: 1144-1150.
38. Bjorck, P (2001). Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 98: 3520-3526.
39. Jonasch, E and Haluska, FG (2001). Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55.
40. Platsoucas, CD, Fox, FE, Oleszak, E, Fong, K, Nanno, M, Ioannides, CG et al. (1989). Regulation of natural killer cytotoxicity by recombinant α interferons. Augmentation by IFN-α7, an interferon similar to IFN-αJ. Anticancer Res 9: 849-858.
41. Vertuani, S, Bazzaro, M, Gualandi, G, Micheletti, F, Marastoni, M, Fortini, C et al. (2002). Effect of interferon-α therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 32: 144-154.
42. Gilliet, M and Liu, YJ (2002). Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195: 695-704.
43. Dalod, M, Salazar-Mather, TP, Malmgaard, L, Lewis, C, Asselin-Paturel, C, Brière, F et al. (2002). Interferon α/β and interleukin 12 responses to viral infections: Pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 195: 517-528.
44. Nemunaitis, J, Ganly, I, Khuri, F, Arseneau, J, Kuhn, J, McCarty, T et al. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 60: 6359-6366.
45. Kirk, CJ, Hartigan-O'Connor, D, Nickoloff, BJ, Chamberlain, JS, Giedlin, M, Aukerman, L et al. (2001). T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Res 61: 2062-2070.
46. Hillinger, S, Yang, SC, Zhu, L, Huang, M, Duckett, R, Atianzar, K et al. (2003). EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J Immunol 171: 6457-6465.
47. Guo, J, Wang, B, Zhang, M, Chen, T, Yu, Y, Regulier, E et al. (2002). Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9: 793-803.
48. Singh, PK, Jia, HP, Wiles, K, Hesselberth, J, Liu, L, Conway, BA et al. (1998). Production of β-defensins by human airway epithelia. Proc Natl Acad Sci USA 95: 14961-14966.
49. Inaba, K, Inaba, M, Romani, N, Aya, H, Deguchi, M, Ikehara, S et al. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702.
50. Gilliet, M, Boonstra, A, Paturel, C, Antonenko, S, Xu, XL, Trinchieri, G et al. (2002). The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195 953-958.